Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Titan MedicalImpedimedAdvanced OncotherapyKromek GroupCyclopharm
SymbolTSE:TMDASX:IPDLON:AVOLON:KMKN/A
Price Information
Current PriceC$0.71A$0.17GBX 39.50GBX 20N/A
52 Week RangeN/AN/ABuyN/AN/A
Analyst Ratings
Consensus RecommendationN/AN/ABuyN/AN/A
Consensus Price TargetN/AN/AGBX 155N/AN/A
% Upside from Price TargetN/AN/A292.41% upsideN/AN/A
Trade Information
Market CapC$48.00 million$83.70 million£93.85 million£68.91 million$95.49 million
BetaN/AN/AN/AN/AN/A
Average Volume125,686N/A79,755290,238N/A
Sales & Book Value
Annual RevenueN/A$4.16 millionN/A£14.52 million$15.69 million
Price / SalesN/A20.14N/A4.750.00
CashflowC$0.33 per shareA$0.02 per shareGBX 1.80 per shareGBX 5.77 per shareN/A
Price / Cash2.157.2721.943.4716.00
Book ValueC($0.59) per shareA$0.04 per shareGBX 20 per shareGBX 17.80 per shareA$0.20 per share
Price / BookN/A3.93N/A0.010.00
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($2.49)A($0.06)GBX (14)GBX (0.10)A($0.04)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AA$0.01
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A55.71%15.78%44.35%
Current Ratio0.50%2.55%2.16%5.41%2.15%
Quick Ratio0.26%2.30%0.79%4.87%1.62%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees96893100N/A
Shares Outstanding33.57 million507.26 million237.59 million344.56 million68.90 million
Next Earnings Date11/11/2019 (Estimated)N/AN/AN/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
 Titan MedicalImpedimedAdvanced OncotherapyKromek GroupCyclopharm

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel